MS-245

MS-245 (also known as 5-methoxy-6-methyl-2-aminoindane), is a drug that is a member of the aminoindane class. It was developed in the 1990s by a team at Pfizer and has been researched for its potential use in the treatment of Alzheimer's disease and other memory related disorders.

History[edit | edit source]

MS-245 was first synthesized and studied in the 1990s by a team at Pfizer. The compound was developed as part of a series of aminoindane derivatives that were being investigated for their potential therapeutic effects.

Pharmacology[edit | edit source]

MS-245 is an NMDA receptor antagonist, which means it works by blocking the action of the NMDA receptor, a type of glutamate receptor that is involved in memory and learning. By blocking this receptor, MS-245 may help to reduce the symptoms of Alzheimer's disease and other memory related disorders.

Clinical Trials[edit | edit source]

In preclinical trials, MS-245 showed promise as a potential treatment for Alzheimer's disease. However, further research is needed to determine its efficacy and safety in humans.

References[edit | edit source]

MS-245 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.